12:00 AM
May 20, 2013
 |  BC Week In Review  |  Company News  |  Other News

Clavis cancer news

Clavis said it is undergoing a "significant down scaling" of its operations following the discontinued development of elacytarabine to treat acute myelogenous leukemia in April. Clavis said most of the employees will leave the company by the end of this year, including CEO Olav Hellebo, who is leaving effective May 20. Clavis said it expects operating expenses for the remainder of 2013 to be NOK34-NOK38...

Read the full 304 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >